People · Operator
Named in public records as an officer, director or promoter · active 2015–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Moderna Therapeutics, Inc. | — | Biotechnology | Growth/Late | $451.4M | $19.2B | 2016 |
| Axcella Health Inc. | — | Biotechnology | Series C | $92.8M | $105.5M | 2015 |
Stephen Hoge at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Stephen Hoge on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Noubar Afeyan | 2 | 9 |
| Robert Langer | 1 | 36 |
| Peter Barton Hutt | 1 | 14 |
| Robert Crane | 1 | 7 |
| Lee Babiss | 1 | 5 |
| Lorence Kim | 1 | 5 |
| Robert Connelly | 1 | 4 |
| John Mendlein | 1 | 4 |
| PETER HUTT | 1 | 4 |
| Stephane Bancel | 1 | 4 |
| Charles Cooney | 1 | 4 |
| Henri Termeer | 1 | 3 |
| David Berry | 1 | 3 |
| Gregory Behar | 1 | 2 |
| Catherine A. Sohn | 1 | 2 |
| William Hinshaw | 1 | 2 |
| David R. Epstein | 1 | 2 |
| William D. Baird | 1 | 2 |
| Elizabeth Nabel | 1 | 2 |
| John Barton Mendlein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.